BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30279110)

  • 1. Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.
    Lam VK; Tran HT; Banks KC; Lanman RB; Rinsurongkawong W; Peled N; Lewis J; Lee JJ; Roth J; Roarty EB; Swisher S; Talasaz A; Futreal PA; Papadimitrakopoulou V; Heymach JV; Zhang J
    Clin Lung Cancer; 2019 Jan; 20(1):30-36.e3. PubMed ID: 30279110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
    Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L
    Ann Oncol; 2019 Feb; 30(2):290-296. PubMed ID: 30535340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.
    Zugazagoitia J; Rueda D; Carrizo N; Enguita AB; Gómez-Sánchez D; Díaz-Serrano A; Jiménez E; Mérida A; Calero R; Lujan R; De Miguel E; Gámez P; Díaz-Hellín V; Nuñez JA; Iglesias L; Ferrer I; Paz-Ares L; Ponce-Aix S
    Clin Lung Cancer; 2018 Jan; 19(1):65-73.e7. PubMed ID: 28780976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Utility of Cell-Free DNA for the Detection of
    McCoach CE; Blakely CM; Banks KC; Levy B; Chue BM; Raymond VM; Le AT; Lee CE; Diaz J; Waqar SN; Purcell WT; Aisner DL; Davies KD; Lanman RB; Shaw AT; Doebele RC
    Clin Cancer Res; 2018 Jun; 24(12):2758-2770. PubMed ID: 29599410
    [No Abstract]   [Full Text] [Related]  

  • 5. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
    Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
    Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
    Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL
    Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
    Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN; Ramalingam SS; Owonikoko TK; Behera M; Force SD; Fernandez FG; Curran WJ; Higgins KA
    Cancer; 2017 Oct; 123(19):3681-3690. PubMed ID: 28608966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
    Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
    Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma.
    Miller TE; Yang M; Bajor D; Friedman JD; Chang RYC; Dowlati A; Willis JE; Sadri N
    J Clin Pathol; 2018 Dec; 71(12):1108-1115. PubMed ID: 30228211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic mutations and immune checkpoint biomarkers.
    Parris BA; Shaw E; Pang B; Soong R; Fong K; Soo RA
    Respirology; 2019 Mar; 24(3):215-226. PubMed ID: 30636374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
    Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
    Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer.
    Laufer-Geva S; Rozenblum AB; Twito T; Grinberg R; Dvir A; Soussan-Gutman L; Ilouze M; Roisman LC; Dudnik E; Zer A; Rotem O; Lanman RB; Peled N
    J Thorac Oncol; 2018 Nov; 13(11):1705-1716. PubMed ID: 30121392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
    Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
    Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing a New qPCR-Based System for Screening Mutation.
    Zhu J; Zhao Y; Liu M; Gonzalez-Rivas D; Xu X; Cai W; Qi H; Dai L; Wang Z; Song X; Jiang G; Yang Y
    Small; 2019 Mar; 15(9):e1805285. PubMed ID: 30677225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
    Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
    J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency and functional characterization of fusion genes in squamous cell carcinoma of the lung.
    Alidousty C; Becker A; Binot E; Hillmer AM; Merkelbach-Bruse S; Budde B; Bäßmann I; Rappl G; Wolf J; Eich ML; Noh KW; Buettner R; Schultheis AM
    Gene; 2024 Feb; 895():148018. PubMed ID: 37981082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing of liquid-based cytology non-small cell lung cancer samples.
    Reynolds JP; Zhou Y; Jakubowski MA; Wang Z; Brainard JA; Klein RD; Farver CF; Almeida FA; Cheng YW
    Cancer Cytopathol; 2017 Mar; 125(3):178-187. PubMed ID: 28085233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-Generation Sequencing Approach to Non-Small Cell Lung Carcinoma Yields More Actionable Alterations.
    Mehrad M; Roy S; Bittar HT; Dacic S
    Arch Pathol Lab Med; 2018 Mar; 142(3):353-357. PubMed ID: 29219616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.